Denosumab as a potential therapeutic option for leiomyosarcoma with osteoclast-like giant cells: A case report

Mol Clin Oncol. 2018 Jan;8(1):30-33. doi: 10.3892/mco.2017.1489. Epub 2017 Nov 6.

Abstract

Bone leiomyosarcoma is a rare primary osseous malignant tumor with a high metastatic potential. Similar to other bone sarcomas, high histological grade and tumor stage are predictive of a poor outcome. We herein present our experience with treating a 64-year-old woman with bone leiomyosarcoma accompanied by multiple bone metastases. A biopsy revealed occasional osteoclast-like giant cells. In addition to radiation therapy, the osteoclastogenesis inhibitor denosumab was administered but the patient did not undergo adjuvant chemotherapy or surgery. Good clinical and short-term radiological responses to denosumab have been observed for 2 years. Therefore, denosumab may represent a viable treatment option without the need for adjuvant chemotherapy.

Keywords: bone tumor; denosumab; leiomyosarcoma; osteoclast-like giant cells.